Literature DB >> 8245503

GRO-alpha mRNA is selectively overexpressed in psoriatic epidermis and is reduced by cyclosporin A in vivo, but not in cultured keratinocytes.

T Kojima1, M A Cromie, G J Fisher, J J Voorhees, J T Elder.   

Abstract

Interleukin (IL)-8 and gro peptides are members of the intercrine-alpha family of chemotaxins known to be present in biologically active form in psoriasis lesions. However, the relative contribution of the three different gro genes to the expression of this material is unknown, as is the stimulus for gro overexpression in psoriatic lesions. To address these questions, Northern blot and semiquantitative polymerase chain reaction analysis were performed on RNA extracted from keratome biopsies of normal skin, untreated plaques of psoriasis, or plaques treated for 1 week with low-dose cyclosporin A (CsA). Northern blot analysis revealed a significant correlation between gro and IL-8 mRNA levels in psoriasis lesions from 26 different individuals (r = 0.61, p = 0.0009), and overexpression of gro was markedly reduced by CsA prior to detectable clinical improvement (79.3%, p = 0.01, n = 22). To determine which form(s) of gro were overexpressed in psoriatic lesions, total keratome RNA (1 microgram) was analyzed by semiquantitative reverse transcription-polymerase chain reaction (SQRT-PCR). In five patients known to markedly overexpress gro and IL-8 mRNAs by Northern blotting, gro-alpha was approximately six times more abundant than gro-beta, and 25 times more abundant than gro-gamma. In cultured human keratinocytes, all three forms of gro mRNA were increased by IL-1 alpha or by interferon (IFN)-gamma plus tumor necrosis factor (TNF)-alpha. However, in contrast to the situation in vivo, CsA had no inhibitory effect on cytokine-stimulated gro expression in cultured keratinocytes. Taken together, these results demonstrate that the gro-alpha gene is selectively overexpressed in psoriatic lesions and strongly suggest that overexpression of gro is a keratinocyte response to activated T cells in psoriasis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8245503     DOI: 10.1111/1523-1747.ep12371692

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  5 in total

1.  Increased circulating concentrations of growth-related oncogene (GRO)-alpha in patients with inflammatory bowel disease.

Authors:  Keiichi Mitsuyama; Osamu Tsuruta; Nobuo Tomiyasu; Kosuke Takaki; Asuka Suzuki; Junya Masuda; Hiroshi Yamasaki; Atsushi Toyonaga; Michio Sata
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

2.  Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis.

Authors:  Andrew M Lin; Cory J Rubin; Ritika Khandpur; Jennifer Y Wang; MaryBeth Riblett; Srilakshmi Yalavarthi; Eneida C Villanueva; Parth Shah; Mariana J Kaplan; Allen T Bruce
Journal:  J Immunol       Date:  2011-05-23       Impact factor: 5.422

3.  IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy.

Authors:  B H Lemster; P B Carroll; H R Rilo; N Johnson; A Nikaein; A W Thomson
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

4.  Distributions of melanoma growth stimulatory activity of growth-regulated gene and the interleukin-8 receptor B in human wound repair.

Authors:  L B Nanney; S G Mueller; R Bueno; S C Peiper; A Richmond
Journal:  Am J Pathol       Date:  1995-11       Impact factor: 4.307

5.  Transcriptome analysis of psoriasis in a large case-control sample: RNA-seq provides insights into disease mechanisms.

Authors:  Bingshan Li; Lam C Tsoi; William R Swindell; Johann E Gudjonsson; Trilokraj Tejasvi; Andrew Johnston; Jun Ding; Philip E Stuart; Xianying Xing; James J Kochkodan; John J Voorhees; Hyun M Kang; Rajan P Nair; Goncalo R Abecasis; James T Elder
Journal:  J Invest Dermatol       Date:  2014-01-17       Impact factor: 8.551

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.